AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03168386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive motor rehabilitation
Description: Intensive motor rehabilitation during subacute stroke phase
Study NCT03991819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
Study NCT03991819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
Study NCT00642382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Agilus
Description: Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
Study NCT00642382 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
Study NCT03931720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study NCT02088918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Study NCT02088918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide/Metformin
Study NCT02088918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT03646201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FFF
Description: FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
Study NCT01379391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Thrombopoietin (rHTPO)
Description: Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT.
Study NCT00759291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acipimox
Description: 250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Study NCT00759291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Study NCT01808482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: 100 mg/mL GSK2618960
Description: 100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
Study NCT01808482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: matching placebo
Description: Matching placebo
Study NCT01808482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Dose of GSK2618960 decided from Part A
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
Study NCT01808482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B: matching placebo
Description: Matching placebo
Study NCT01808482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: Dose of GSK2618960 decided from Part A and B
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
Study NCT00815685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid
Description: Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
Study NCT02286778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acetogenins
Description: Acetogenins BID for 12 months
Study NCT02286778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00406653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months
Study NCT00406653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Study NCT00406653 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: abatacept
Description: \~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Study NCT01005433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
Study NCT01005433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
Study NCT02590809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment BX1514M
Description: X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
Study NCT02590809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for 30 days
Study NCT02590809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walk distance test
Description: Walk distance test during 6 minutes
Study NCT02590809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk distance test
Description: Walk distance test during 6 minutes
Study NCT02590809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise echocardiography
Study NCT02590809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Study NCT03650478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
Description: Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
Study NCT03650478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
Description: Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
Study NCT02044211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care for Heart Failure
Description: Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist.
Study NCT02044211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care for Depression
Description: The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable.
Study NCT01768520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks
Description: 1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg
Study NCT01768520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Study NCT01768520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Study NCT04697303 — intervention group
Intervention type: OTHER
Intervention: anorectal function test
Description: anorectal function test
Study NCT00361348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02581410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Study NCT02581410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Study NCT00658385 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Description: Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected.
Study NCT00759941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic solution (Azopt)
Description: One drop three times a day in both eyes for 3 months
Study NCT00759941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo eye drops
Description: One drop three times a day in both eyes for 3 months
Study NCT00759941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% ophthalmic solution (Xalatan)
Description: One drop once a day in both eyes for 3 months
Study NCT00759941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% ophthalmic solution (Xalatan)
Description: One drop once a day in both eyes for 3 months
Study NCT00472030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
Study NCT03613285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional brackets
Description: conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
Study NCT03613285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smart clip passive self ligating brackets
Description: smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
Study NCT03613285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empower active self ligating brackets
Description: Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
Study NCT00722852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 100 mg (b.i.d.)
Study NCT00722852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg (b.i.d.)
Study NCT03646500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrobulbar Block
Description: Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
Study NCT03646500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered as intravenous infusion prior to transcleral diode procedure
Study NCT03203720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
Study NCT03035968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta therapy
Study NCT03035968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Study NCT02920333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional rehab training
Description: Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
Study NCT02920333 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional rehab training
Description: Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
Study NCT02920333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
Study NCT02920333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
Study NCT02920333 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
Study NCT01603186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Tablets 25 mg
Description: 25 mg tablet once a day
Study NCT01603186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Fumarate
Description: 25 mg tablet once a day
Study NCT01947192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with chlorhexidine
Description: Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
Study NCT01947192 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Water pre-treatment
Description: Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
Study NCT00472030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone, to a maximum dose of 0.5 mg/kg/day.
Study NCT04246567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mean Blood Pressure (MBP)
Description: Mean blood pressure (MBP) for patients 50-65 mmHg
Study NCT04246567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add to 0.5 mcg / kg fentanyl.
Description: When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
Study NCT02893930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT03143660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
Study NCT03143660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Materials
Description: The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
Study NCT01314820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline injection
Description: 20 cc normal saline injection into knee joint
Study NCT01314820 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: no saline injection
Study NCT01137526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: Subjects will take study drug once daily for 12 weeks
Study NCT01137526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Subjects will take study drug once daily for 12 weeks.
Study NCT01137526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take study drug once daily for 12 weeks
Study NCT00688831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Solution for iv infusion , single dose
Study NCT00688831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl solution for iv infusion, single dose
Study NCT02012413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PST - Pulsed Signal Therapy
Description: PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes